Monograph Details
|
|
Neoplasms
> Miscellaneous oncology agents
|
|
REVLIMID |
| Manufacturer |
|
Celgene Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Immunomodulator. |
| Generic Name |
|
Lenalidomide 5mg, 10mg, 15mg, 25mg; caps. |
| Indications |
|
Multiple myeloma (in combination with dexamethasone) in patients who have received at least one prior therapy. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Do not break, chew, or open caps. Swallow whole with water. ≥18yrs: initially one 25mg cap daily on Days 1–21 of each 28-day cycle. Dose adjustments: see literature. |
| Contraindications |
|
Pregnancy (Cat. X). Nursing mothers. Women who may become pregnant. |
| Precautions |
|
Must register patient in RevAssist program; patient must understand toxicity with fetal exposure. Counsel patient on need for contraception; female: use 2 forms of contraception 1 month before, during, and 1 month after therapy; male: use condom during and 1 month after therapy; obtain 2 negative pregnancy tests (one within 10–14 days, and then another within 24 hours prior to starting therapy), repeat at least weekly for 1st month then every 4 weeks; get informed consent. Monitor for signs/symptoms of thromboembolic events. Renal impairment (monitor). Obtain CBCs every 2 weeks for first 3 months, then monthly. Maximum 1 month per Rx. |
| Interactions |
|
Monitor digoxin. |
| Adverse Reactions |
|
Birth defects, thrombocytopenia, neutropenia, GI upset, pruritus, rash, fatigue, arthralgia, pyrexia, back pain, cough, dizziness, headache, dyspnea, blurred vision, muscle cramp; thrombosis/embolism. |
| Extra Text |
|
Note: Available only through RevAssist program. Report any suspected fetal exposure to the FDA at (800) FDA-1088 and Celgene at (888) 423-5436. |
| How Supplied |
Caps 5mg, 10mg—30, 100
15mg—21, 100
25mg—25, 100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
